Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Judith Greciet on Targeting Iron Dysregulation: PulseSight’s Next-Generation Approach to Geographic Atrophy  
Shots:  PulseSight Therapeutics is advancing a novel approach to Geographic Atrophy (GA) with PST-611, a first-in-class non-viral gene therapy designed to restore iron homeostasis by targeting transferrin biology—an upstream driver of retinal degeneration.  At ARVO 2026, PST-611 delivered encouraging Phase I results, demonstrating an excellent safety and tolerability profile, stable visual acuity, and early signals of potential functional…
June 22, 2026
HLTH Europe 2026: How Withings Is Advancing GLP-1 Outcomes Through Connected Care and Real-World Data 
Shots:  HLTH Europe 2026 brought together healthcare leaders, innovators, and policymakers to explore the future of healthcare delivery, digital transformation, patient engagement, and value-based care. Among the key topics discussed was the growing role of GLP-1 therapies and how data-driven care models are reshaping chronic disease management.  Withings Health Solutions is helping advance this transformation through…
June 19, 2026
IL-33 Breakthrough in COPD: Caterina Brindicci and Frank Sciurba on Tozorakimab’s Phase III Success 
Shots:  Tozorakimab demonstrated a potential first-in-class advantage in COPD, becoming the first IL-33 biologic to achieve positive outcomes across three pivotal Phase III trials (OBERON, TITANIA, and MIRANDA), highlighting the clinical relevance of targeting both reduced and oxidized forms of IL-33 to reduce exacerbations in a broad patient population.  The LUNA Phase III programme enrolled the most comprehensive…
June 15, 2026
Jared Kelly on Immune Priming & Survival Outcomes: Oncolytics Biotech’s Vision for Pelareorep
Shots:  Oncolytics Biotech is advancing pelareorep beyond the traditional standalone therapy model, positioning the platform as a potential immune-priming backbone capable of enhancing immunotherapies, checkpoint inhibitors, chemotherapies, and other oncology treatments across multiple difficult-to-treat tumor settings.  The company continues generating growing survival and immune-engagement data across colorectal, pancreatic, and anal cancers, while emphasizing pelareorep’s potential to “turn cold tumors…
June 3, 2026
Advancing HES Care with AstraZeneca’s FASENRA: Insights from James Teague & Princess U. Ogbogu
Shots:  Could a targeted biologic therapy help address the longstanding unmet needs in hypereosinophilic syndrome (HES)? AstraZeneca’s FASENRA has now received US approval for HES, introducing a once-monthly treatment option for patients living with this rare and often underdiagnosed eosinophilic disorder  Results from the Phase III NATRON trial showed that FASENRA reduced the risk of first HES flare by 65% vs placebo,…
June 1, 2026
Roy Maute on Macrophage Checkpoint Inhibition: Pheast’s Vision for Advancing PHST001 in Solid Tumors 
Shots:  Pheast Therapeutics is redefining innate immunity in oncology with PHST001, an anti-CD24 macrophage checkpoint inhibitor engineered to overcome the limitations of earlier macrophage-targeted therapies and unleash a powerful anti-tumor immune response.  At AACR 2026, PHST001 delivered encouraging early clinical signals with favorable tolerability, clear immune activation, and promising anti-tumor responses across heavily pretreated solid tumor…
May 27, 2026
Dr. Orla Cloak on Manufacturing Excellence: Minaris Vision for Advanced Therapies
Shots:  Minaris is advancing its dual-business strategy through specialized Advanced Therapies and Advanced Testing units, enabling sponsors to streamline development, manufacturing, biosafety testing, and commercialization within one integrated global organization.   Minaris is focused on solving key cell & gene therapy manufacturing challenges by reducing variability, accelerating tech transfer, improving “first time right” execution, and lowering…
May 18, 2026
Ending Prescription Ping-Pong in Specialty Care: Colin Banas, CMO, Timely By DrFirst Shares His Vision  
Shots:  Specialty medication access remains challenged by high costs, fragmented workflows, complex prior authorization requirements, and limited transparency, leading to delays, prescription drop-offs, and suboptimal patient outcomes.  DrFirst is addressing these gaps through AI-powered, workflow-integrated solutions that enable real-time benefits verification, targeted prior authorization automation, and smarter pharmacy routing, shifting care from reactive problem-solving to proactive, frictionless prescribing.  PharmaShots welcomes…
May 4, 2026
Jena Sophia on Breaking the Stress Code: Rewiring High Performance from Within 
Shots:  High performers often operate under a hidden layer of chronic stress, where sustained pressure subtly erodes decision-making, creativity, and emotional regulation, as subconscious patterns and past experiences continuously trigger a low-grade fight-or-flight response that impacts both performance and overall wellbeing  Lasting stress management requires going beyond surface-level techniques to address deep-rooted subconscious programming, where beliefs around identity, success,…
April 20, 2026
Innovation Meets Impact: Jaime Leija on BioLab’s Patient-First Approach
Shots:  BioLab balances innovation with real-world impact through a dual strategy that combines rapid commercialization of FDA-approved or near-market solutions like Imbed with continued investment in long-term innovations such as cureVision and terraplasma, ensuring both immediate clinical needs and future breakthroughs in wound care are effectively addressed.    BioLab’s growth is driven by sharp strategic discipline, focusing on chronic outpatient…
April 13, 2026
Load more